Breakthrough T1D Publishes First Global Consensus on Type 1 Diabetes Screening
Event summary
- Breakthrough T1D published the first international consensus guidance for general population screening of type 1 diabetes (T1D) in Diabetologia on September 10, 2026.
- The guidance, developed by 30 global T1D experts, outlines screening protocols for children aged 2-4, with rescreening at ages 6-8 and 10-15.
- Early detection via islet autoantibody tests can reduce diabetic ketoacidosis (DKA) risk and enable intervention with therapies like teplizumab.
- The consensus is endorsed by 20 global diabetes societies and aligns with Breakthrough T1D's 2024 monitoring guidance.
The big picture
Breakthrough T1D's consensus guidance marks a pivotal shift toward proactive T1D management, aligning with the growing trend of early-stage autoimmune disease detection. The framework could accelerate research into disease-modifying therapies and reshape pediatric diabetes care, though its success hinges on widespread adoption by healthcare providers. With 9.5 million people globally affected by T1D, the guidance addresses a critical gap in preventive care.
What we're watching
- Adoption Pace
- How quickly healthcare systems integrate the screening guidelines into routine practice.
- Therapeutic Impact
- Whether early detection translates to broader adoption of disease-modifying therapies like teplizumab.
- Global Alignment
- The extent to which diverse healthcare systems adapt the consensus guidance to local contexts.